Ruben Alvarez-Sanchez
Overview
Explore the profile of Ruben Alvarez-Sanchez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bahrpeyma S, Jakubiak P, Alvarez-Sanchez R, Caruso A, Leuthardt M, Senn C, et al.
Invest Ophthalmol Vis Sci
. 2024 Oct;
65(12):14.
PMID: 39382881
Purpose: The purpose of this work was to understand the impact of melanin binding on ocular pharmacokinetics after administration of a high-binder model drug via different administration routes. Methods: We...
2.
Jakubiak P, Alvarez-Sanchez R, Fueth M, Broders O, Kettenberger H, Stubenrauch K, et al.
Mol Pharm
. 2021 May;
18(6):2208-2217.
PMID: 34014104
The current standard of care for antivascular endothelial growth factor (VEGF) treatment requires frequent intravitreal (IVT) injections of protein therapeutics, as a result of limited retention within the eye. A...
3.
Hauri S, Jakubiak P, Fueth M, Dengl S, Belli S, Alvarez-Sanchez R, et al.
Pharmaceutics
. 2020 Aug;
12(9).
PMID: 32858986
The burden associated with frequent injections of current intravitreal (IVT) therapeutics may be reduced by long-acting delivery strategies. Binding to serum albumin has been shown to extend the ocular half-life...
4.
Caruso A, Futh M, Alvarez-Sanchez R, Belli S, Diack C, Maass K, et al.
Mol Pharm
. 2019 Dec;
17(2):695-709.
PMID: 31876425
Therapeutic antibodies administered intravitreally are the current standard of care to treat retinal diseases. The ocular half-life () is a key determinant of the duration of target suppression. To support...
5.
Jakubiak P, Cantrill C, Urtti A, Alvarez-Sanchez R
Mol Pharm
. 2019 Nov;
16(12):4890-4901.
PMID: 31670965
A large variety of drugs bind effectively to melanin, and this binding influences their ocular pharmacokinetic and distribution profiles. We aimed to establish a correlation between in vitro melanin binding...
6.
Jakubiak P, Lack F, Thun J, Urtti A, Alvarez-Sanchez R
Mol Pharm
. 2019 Apr;
16(6):2549-2556.
PMID: 30998378
Melanins are biopolymers encompassing a high degree of chemical heterogeneity. Binding of small-molecule drugs to ocular melanin significantly affects the ocular pharmacokinetics, and could serve as a strategy for prolonged...
7.
Jakubiak P, Reutlinger M, Mattei P, Schuler F, Urtti A, Alvarez-Sanchez R
J Med Chem
. 2018 Nov;
61(22):10106-10115.
PMID: 30398862
Binding of drugs to ocular melanin is a prominent biological phenomenon that affects the local pharmacokinetics and pharmacodynamics in the eye. In this work, we report on the development of...
8.
Hermann K, Neuhaus C, Micallef V, Wagner B, Hatibovic M, Aschmann H, et al.
Eur J Pharm Sci
. 2017 Apr;
104:150-161.
PMID: 28366650
For low molecular weight drugs, lipid bilayer permeation is considered the major route for in vivo cell barrier passage. We recently introduced a fluorescence assay with liposomes to determine permeation...
9.
Jakubiak P, Schuler F, Alvarez-Sanchez R
Eur J Pharm Biopharm
. 2016 Sep;
109:43-48.
PMID: 27648958
Thorough understanding and control of the different crystal forms of a drug product is key for fine chemistry and materials science; it ultimately determines the product's physicochemical properties and performance....
10.
Raab S, Wang H, Uhles S, Cole N, Alvarez-Sanchez R, Kunnecke B, et al.
Mol Metab
. 2016 Feb;
5(1):47-56.
PMID: 26844206
Objective: Type 2 diabetes and obesity are emerging pandemics in the 21st century creating worldwide urgency for the development of novel and safe therapies. We investigated trace amine-associated receptor 1...